This 3 minute narrated report highlights the FDA pharmaceutical activity for 2022 and 2023..  Learn which subsystems and regulations present elevated regulatory compliance risk.

In this discussion the top cited pharma subsystems and associated regulations are highlighted along with a top line remediation plan to improve performance/reduce regulatory risk in these areas.

Building upon remediation part one this discussion provides additional detail and insights into recommended tasks and actions for creating a comprehensive action plan to address the top areas of pharmaceutical regulatory risk identified in the 2022/2023 Pharmaceutical FDA Citation Analysis.